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PATHOGENESIS OF LIGHT CHAIN-INDUCED DYSFUNCTION IN CARDIAC 
AMYLOIDOSIS  
CHRISTINA ANNAMARIE SNYDER 
 
ABSTRACT 
Although a rare disease, light chain (LC) amyloidosis (AL) is the most 
common systemic amyloidosis in developed countries.  It is caused by an 
overproduction of immunoglobulin LC proteins in bone marrow plasma cells.  In 
AL amyloidosis, LCs that are prone to misfolding and insolubility will aggregate, 
form fibrils, and deposit themselves in various tissues, thereby causing organ 
dysfunction.  The most fatal manifestation of AL amyloidosis is associated with 
cardiac involvement, defined by the presence of extracellular AL amyloid 
deposits within the heart.  Cardiac amyloid infiltration typically leads to diastolic 
dysfunction followed by heart failure and has a median survival of approximately 
6 months from the time of diagnosis if untreated. 
Clinical observation suggests that a reduction in circulating LCs results in 
an improvement in heart failure symptoms despite minimal changes in amyloid 
deposition.  This has led to the concept that LCs themselves are cytotoxic to 
cardiomyocytes.  Recent studies indicate that AL LCs induce oxidative stress, 
cellular dysfunction, and apoptosis (programmed cell death) in cardiomyocytes 
via a p38α mitogen-activated protein kinase (MAPK) mechanism.  They may 
therefore be a target for amyloidosis therapy.  By understanding how LCs cause 
	   vi	  
cardiac dysfunction, we can target this process with therapies and utilize 
downstream measures of LC activity as diagnostic and prognostic tools. 
The objective of this study was to determine the role of autophagy in AL 
amyloidosis.  Autophagy is the intracellular process of degrading aging or 
dysfunctional cellular components.  Autophagy can be beneficial by preventing 
proteotoxicity and providing nutrients, amino acids, and other necessities during 
times of cellular stress.  On the other hand, increased autophagy, like apoptosis, 
may mediate cellular death depending on the type of stimulus and its duration.  
Autophagy is induced by a variety of stimuli, including oxidative stress.  AL has 
been demonstrated to increase reactive oxygen species (ROS), and it is 
unknown if autophagy mediates cardiomyocyte dysfunction in AL cardiac 
amyloidosis.  We thus sought to determine if it is a factor in amyloid 
cardiotoxicity.  We explored the ERK1/2, p38, and JNK MAPK pathways in 
particular, since MAPK signaling cascades regulate several transcription factors 
involved in the cell cycle and p38α has been implicated in ROS-induced cardiac 
AL amyloidosis. 
Adult rat ventricular myocytes (ARVM) were harvested from healthy adult 
male rats and exposed to a variety of experimental conditions in vitro.  ARVM 
were treated with vehicle control, human LC obtained from a patient without 
cardiac involvement, a positive control (aldosterone), and human AL light chains 
obtained from a patient with AL cardiac amyloidosis in the presence or absence 
of UO126, SB203580, or SP600125 (specific inhibitors of ERK1/2, p38, and JNK, 
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respectively).  The resulting protein expression levels of autophagy indicators 
LC3II and ATG4B in cardiomyocytes were analyzed by Western blotting.  The 
ratio of phosphorylated to total ERK1/2 protein expression was also explored.   
We found that AL light chains did not contribute to autophagy via the 
ERK1/2, p38, or JNK pathways.  In contrast to our previous unpublished findings, 
the protein levels of autophagy indicators in AL-treated ARVM did not differ from 
vehicle control levels, suggesting that AL did not activate autophagy.  However 
non-cardiomyopathic light chains (LC) did increase LC3II expression in ARVM, 
despite their human source exhibiting no clinical indications of cardiac 
involvement.  This implies that autophagy induced by non-cardiomyopathic LCs 
may be beneficial and protect against the development of the cardiotoxicity seen 
in AL cardiac amyloidosis.  
Further studies are necessary to understand the effect of autophagy in the 
heart and its role in cardiac amyloidosis.  Continuing to explore the underlying 
mechanisms of AL light chain toxicity will contribute to the development of 
diagnostic, prognostic, and treatment strategies for AL amyloidosis.
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INTRODUCTION 
I. Amyloidosis 
Amyloidosis represents a variety of disorders characterized by the 
deposition of amyloid in tissues and organs.  Amyloid is formed when normally 
soluble proteins are misfolded and become insoluble, developing into protein 
aggregates that arrange themselves into antiparallel β-sheets and manifest as 
rigid fibrils (Figure 1)1,2.  Potentially pathogenic proteins can be led to misfolding 
in a variety of ways, including an intrinsic structural propensity that manifests with 
advanced age or increased serum concentration, amino acid mutations, or 
proteolytic alteration of the protein precursor1,3.  Dozens of distinct amyloid 
precursor proteins, each with heterogenous protein sequence and structure and 
function, have been identified as amyloidogenic.  These proteins are capable of 
misfolding, aggregation, fibril formation, and tissue deposition4.   
Despite the diversity of amyloidogenic proteins, the nonbranched fibrils 
that they form are largely indistinguishable from one another.  Extracellular 
deposits of amyloid fibrils can be identified using light microscopy by staining with 
Congo red, sulfated Alcian blue, or thioflavin T.  With Congo red staining, amyloid 
fibrils exhibit a characteristic apple-green birefringence when visualized under 
polarized light.  The deposition of amyloid in various locations disrupts normal 
tissue and organ function, thereby causing disease.  Because amyloidogenic 
proteins are synthesized by different organs and can affect different organs 
throughout the body, they each require distinct therapeutic approaches. 
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Figure 1.  Amyloid Fibrils.  Various precursor proteins can generate amyloid fibrils.  
Misfolded or structurally altered forms of these proteins can aggregate to form 
unbranched fibrils that are 7-10 nm wide and composed of β-sheets.  The fibrils are 
deposited extracellularly in tissues and disrupt normal tissue function.  When stained 
with Congo red and viewed under polarized light, tissues with amyloid deposit exhibit 
apple-green birefringence. Figure reproduced from Merlini & Belotti, 20031. 
 
 
Amyloidosis may present as either a localized or systemic disease, 
depending upon whether a single organ or multiple organs are affected.  Distinct 
amyloid precursor proteins can each cause a specific type of amyloid disease 
which will determine a patient’s clinical presentation, treatment options, and 
prognosis.  At least 30 proteins have been identified as causative agents of 
human amyloid diseases, ranging from localized central nervous system 
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conditions such as Alzheimer’s (caused by β Amyloid protein, Aβ) and 
Creutzfeldt-Jakob Disease (CJD, caused by prions, APrP) to systemic conditions 
such as AL amyloidosis (caused by immunoglobulin light chains) or ATTR 
amyloidosis (caused by transthyretin)4,5.  A list of human amyloid fibril proteins 
and their precursors is presented in Table 1, as adapted from Guan et al., 2011 
and Sipe et al., 2012.   The nomenclature used here is based upon the 2012 
recommendations of the Nomenclature Committee of the International Society of 
Amyloidosis4.  The amyloid fibril protein is designated “A” and followed by a suffix 
which is an abbreviation of the precursor protein name, e.g. amyloidogenic 
immunoglobulin light chain (AL) or amyloidogenic transthyretin (ATTR). 
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Table 1. Human amyloid fibril proteins and their precursors4,6. 
Fibril 
Protein 
Precursor Protein Precursor 
Protein Site 
of Production 
Systemic 
and/or 
Localized 
Acquired 
or Here-
ditary 
 Target Organs 
AL Immunoglobulin (Ig)  
Light chain 
Bone Marrow S, L A All organs except CNS 
(especially heart, kidney, 
liver, soft tissue, ANS, PNS) 
AH Ig Heavy chain Bone Marrow S, L A All organs except CNS 
Aβ2M β2-microglobulin, wild 
type (WT) 
Ubiquitous in 
nucleated cells 
L A Musculoskeletal system 
  β2-microglobulin, variant  S H ANS 
ATTR Transthyretin, WT Liver S, L A Heart, Tenosynovium 
  Transthyretin, variants  S H PNS, ANS, heart, eye 
AA (Apo) serum amyloid A Liver S A All organs except CNS 
AApoA 
I 
Apolipoprotein A I, 
variants 
Liver and small 
intestine 
S H Heart, liver, kidney, PNS, 
testis, larynx, skin 
AApoA 
II 
Apolipoprotein A II, 
variants 
Liver and small 
intestine 
S H Kidney 
AApoA 
IV 
Apolipoprotein A IV, WT Intestine S A Kidney medulla and 
systemic 
AGel Gelsolin, variants Ubiquitous S H PNS, cornea 
ALys Lysozyme, variants Ubiquitous S H Kidney 
ALect2 Leukocyte chemotactic 
factor-2 
Liver S A Kidney, primarily 
AFib Fibrinogen α, variants Liver S H Kidney, primarily 
ACys Cystatin C, variants Ubiquitous S H PNS, skin 
ABri ABriPP, variants Brain, kidney, 
pancreas 
S H CNS 
ADana ADanPP, variants Brain, kidney, 
pancreas 
L H CNS 
Aβ Aβ protein precursor, WT Brain L A CNS 
  Aβ protein precursor, var  L H CNS 
APrP Prion protein, wild type Infection agent L A CJD, Fatal insomnia 
  Prion protein variants  L H CJD, GSS, Fatal insomnia 
ACal (Pro)calcitonin Thyroid L A C-cell thyroid tumors 
AIAPP Islet amyloid 
polypeptideb 
Pancreas L A Pancreas 
AANF Atrial natriuretic factor Atria L A Cardiac atria 
APro Prolactin Pituitary L A Pituitary 
AIns Insulin Pancreas L A Iatrogenic, local injection 
ASPC Lung surfactant protein Lung L A Lung 
AGal7 Galectin 7 Skin L A Skin 
ACor Corneodesmin Skin L A Skin, hair follicles 
AMed Lactadherin Aortic Media L A Senile aortic, media 
AKer Kerato-epithelin Eye L A Cornea, hereditary 
ALac Lactoferrin Eye L A Cornea 
AOaap Odontogenic ameloblast-
associated protein 
Teeth L A Odontogenic tumors 
ASem1 Semenogelin 1 Seminal 
Vesicles 
L A Seminal Vesicles 
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Systemic amyloidosis presents a great therapeutic challenge due to its 
effects on multiple organs, which can include kidneys, heart, liver, and soft 
tissues.  The most critical and fatal manifestation of systemic amyloidosis is 
associated with cardiac involvement7.  Cardiac amyloidosis is defined by the 
presence of extracellular amyloid deposits within the heart.  The infiltration of 
amyloid fibrils occurs in the atria, ventricles, intramyocardial vessels, and 
occasionally epicardial vessels (Figure 2)8.  This often leads to wall thickening of 
all four chambers, increased stiffness, impaired ventricular compliance, and 
inadequate ventricular filling.  This amyloid infiltration results in diastolic 
dysfunction and can present as congestive heart failure due to diastolic heart 
failure.  
Of the systemic amyloidoses listed in Table 1, nine of them are known to 
involve the heart6.  The predominant amyloidoses with cardiac involvement are 
AL, ATTR, AA, and AANF amyloidosis.  The most common of these, and indeed 
the most common overall systemic amyloidosis, is AL amyloidosis7.  
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Figure 2. Hearts with severe amyloid infiltration.  The autopsy specimens shown 
here reveal extensive amyloid deposit, which is visible as biventricular thickening and 
thickening of the septum. Note the reduced size of the ventricular cavities.  Figures 
reproduced from Falk & Dubrey, 2010, and Falk, 20058,9. 	  
II. Incidence and Epidemiology 
The incidence of AL amyloidosis in the United States is estimated at 
approximately 1 case per 100,000 person-years10.  Therefore, 2000-3000 new 
diagnoses of AL amyloidosis are expected to occur in the US each year.   This is 
roughly 3 to 10 times less than well-known cancers such as multiple myeloma, 
acute lymphocytic leukemia, and Hodgkin lymphoma11.  AL amyloidosis usually 
affects people after their fifth decade, with a median age at diagnosis of 
approximately 60 years7,12.  It tends to occur slightly more in men than in women, 
and it is less common in people of non-Caucasian origins7,12. 
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III. Survival and Mortality Rates 
For patients with AL amyloidosis, the risk of early death is high.  Nearly 
half of patients die within a year of diagnosis13.   In 1995 Kyle & Gertz estimated 
the 5-year survival rate after the time of diagnosis to be 7%.  Nearly two decades 
later, Kumar et al. calculated that the 5-year survival rate had improved to 28%, 
likely due to improvement in therapeutic options13.  Yet the median overall 
survival duration has improved minimally, from 1.2 years (1977-1996) to 1.5 
years (1997-2006)7,12,13.   For patients presenting with congestive heart failure, 
the median duration of survival is even less.  It was estimated to be 4 to 9 
months7,12.  This outcome is especially dismal when compared to other types of 
heart failure.  For example, data from the first fifty years of the Framingham Heart 
Study show a 5-year survival rate of 41% in men and 55% in women after the 
onset of heart failure, with an improvement of 12% per decade14.  Thus, although 
AL amyloidosis with cardiac involvement is relatively rare, it represents a form of 
heart failure whose prognosis is especially poor. 
 
IV. Etiology 
The underlying etiology of AL amyloidosis is associated with the 
overproduction of immunoglobulin (Ig) light chain (LC) proteins by plasma cells in 
the bone marrow.  Immunoglobulins are typically heterotetramers formed from 
two heavy chains paired with two light chains.  A light chain is composed of a 
variable domain (V) and a constant domain (C)15,16.  Humans have two major 
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families of variable domains, called lambda (λ) and kappa (κ).   The 
combinatorial pairing of variable domain genes allows for sequence variability in 
the Ig molecule, with the possibility of forming thousands of different light chain 
sequences.  The overall structure of the LC variable domain contains 9 β-strands 
that are packed together to form antiparallel β-sheets16.  It is through these 
secondary structures that the light chains interact with the heavy chains, and 
have the potential to form LC dimers when they are occasionally released into 
circulation as free light chain proteins. 
The precise mechanisms that govern LC protein misfolding and 
aggregation are unknown.  The sequence variability of light chains adds to the 
complexity of AL amyloidosis, because each patient can possess a unique 
amyloidogenic protein.  However certain characteristics have been shown to 
make a soluble LC protein more likely to assemble into amyloid fibrils.  The 
germline λ is considered intrinsically more amyloidogenic than κ because the 
number of AL cases favors λ by 2:1, whereas the distribution of Ig variable gene 
usage in normal populations favors κ by 3:117.  Two Vλ gene segments in 
particular, Vλ6a and Vλ3r, are thought to contribute to over 40% of amyloidogenic 
λ light chains1,3,18.  Even single amino acid mutations have been shown to greatly 
decrease LC thermodynamic stability and facilitate fibril formation19,20.  More 
likely a combination of destabilizing and structurally disruptive mutations leads to 
the protein’s amyloidogenic propensity.  Environmental factors such as 
concentration, temperature, pressure, ionic strength, and agitation may also 
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affect fibril formation, and may account for the variation in the organs affected by 
AL16.  Ultimately the determinants of LC amyloidogenicity are multifactorial and 
incompletely understood. 
Because the amyloidogenic LC protein originates in the plasma cell, AL 
amyloidosis is also associated with multiple myeloma.  Multiple myeloma is a 
cancer of plasma cells.  As their numbers increase in bone marrow and continue 
to produce proteins, high concentrations of light chains can lead to amyloidosis.  
Approximately 10% of patients with multiple myeloma develop coexisting AL 
amyloidosis21,22. 
Amyloid deposits are harmful to the human body because they disrupt 
normal tissue structures and can thereby affect their ability to function.  It was 
initially thought that this physical, mechanical substitution of tissue by amyloid 
fibrils was sufficient to explain their detrimental effects in AL amyloidosis (Figure 
3).  However evidence has emerged to suggest that amyloidogenic LC proteins 
may be harmful independent of their deposition, i.e. the prefibrillar aggregates 
themselves are cytotoxic.  Light chains isolated from patients with cardiac 
involvement have been shown to directly impair cardiac function in vitro and in 
vivo without being deposited in the heart23–26.  These data are consistent with 
clinical observations that a reduction in circulating free light chains can benefit 
patients despite the persistence of amyloid deposits.  
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Figure 3. Cardiac biopsies showing normal findings vs. amyloid infiltration.  
Normal findings (left) show muscle fibers staining pink, whereas amyloid findings (right) 
show extensive AL infiltration staining light pink-purple around the muscle fibers stained 
red.  Normally cardiomyocytes are packed closely together, and various intercellular 
junctions allow the muscle fibers to contract smoothly as a single unit.  In cardiac 
amyloidosis, the amyloid fibril deposition disrupts the careful arrangement of muscle 
fibers.  Figure reproduced from Quarta et al., 201227. 
 
The mechanism by which circulating AL protein can cause cardiac 
dysfunction is currently being investigated.  Shi et al. report that amyloidogenic 
light chains can induce oxidative stress, cardiomyocyte contractile dysfunction, 
and cardiomyocyte apoptosis through activation of p38α mitogen-activated 
protein kinase (MAPK)25.  The MAPK signaling cascades regulate several 
transcription factors that can alter the production of genes involved in the cell 
cycle.  Three well characterized MAPK pathways are the Extracellular-signal-
Regulated Kinases 1/2 (ERK1/2), c-Jun N-terminal Kinases (JNK), and p38 MAP 
Kinases.  Up- or down-regulation of factors in these pathways can affect cell 
proliferation, differentiation, and death. 
The three main mechanisms by which cells undergo death and 
degradation are necrosis, apoptosis, and autophagy.  Necrosis is a pathologic 
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process by which cells are chaotically and indiscriminately destroyed over a field 
of injury.  This premature death occurs as the result of external factors such as 
trauma, toxins, or infection.  Apoptosis is often a physiological process by which 
cells undergo cell death in a programmed, controlled manner.  It can be induced 
by cellular aging, stress, hypoxia, viral infection, and many other means.  
Autophagy is a physiological mechanism of degrading and recycling unnecessary 
or dysfunctional cellular components.   
Autophagy can be induced by various cellular stresses, including nutrient 
deprivation, reactive oxygen species (ROS), DNA damage, protein aggregates, 
damaged organelles, and intracellular pathogens28.  It often serves a 
cytoprotective role, enabling survival during times of cellular starvation or 
damage.  In disease states, it is unclear whether autophagy is the cause of cell 
death or actually an adaptive response in attempt to prevent it.  Autophagy can 
be activated by oxidative stress, which has been shown to be induced through 
AL24,25.  Since autophagy has yet to be explored in the context of amyloidosis, it 
is the focus of this research.  
 
V. Clinical Presentation 
Because amyloid deposits can accumulate in different locations 
throughout the body, they generate a wide range of clinical symptoms.  The most 
common organs affected by AL amyloidosis are the kidneys, heart, liver, 
gastrointestinal (GI) tract, peripheral and autonomic nerves, and various soft 
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tissues.  Table 2 shows the approximate frequency of clinically relevant organ 
involvement for AL amyloidosis patients based on analysis of 434 patients at the 
Mayo Clinic (Rochester, Minnesota, USA) by Gertz, et al. in 2011 and 705 
patients of the Pavia Amyloid Center (Pavia, Italy) by Obici et al. in 200518,29.   
Table 2. Percentage of clinically relevant organ involvement in AL Amyloidosis 
patients18,29.  Due to the fact that patients can experience symptoms from multiple 
organs, the cumulative totals for organ system involvement are greater than 100%.  
Asterisk (*) indicates no data available. 
Organ Mayo Clinic Pavia Amyloid Center 
Kidney 74% 70% 
Heart 60% 49% 
Liver 27% 14% 
ANS, PNS 20% 12% 
Lung * 2% 
GI 8% * 
 
Dubrey et al. examined associated features of AL amyloidosis in 232 
patients with cardiac involvement at the Amyloid Research and Treatment 
Program at Boston University School of Medicine (Figure 4)12.  The most 
common symptoms described were fatigue and weakness.  Other common 
clinical features included proteinuria, carpal tunnel syndrome, weight loss 
(despite marked edema), periorbital purpura (“racoon eyes”), macroglossia 
(enlarged tongue), hepatomegaly, and signs of congestive heart failure12,30.  GI 
tract involvement was also more common among patients with cardiac 
amyloidosis, although it may be asymptomatic.  Criteria for the definition of organ 
involvement were later developed at the 10th International Symposium on 
Amyloid and Amyloidosis31.  In addition to helping researchers and clinicians 
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assess organ involvement, these guidelines also aid in the evaluation of a 
patient’s response to treatment. 
 
Figure 4.  Other organ systems involved in AL Amyloidosis patients with cardiac 
involvement.  Due to the systematic nature of AL amyloidosis, it is able to affect 
multiple organs.  Therefore the cumulative totals for organ system involvement are 
greater than 100%.  Less than 4% of patients experienced cardiac symptoms in the 
absence of clinical evidence for any other organ involvement.  Adapted from Dubrey et 
al., 199812. 
 
Clinical features of cardiac involvement might be initially difficult to 
attribute to amyloidosis due to their nonspecific nature.  Cardiac biomarkers such 
as troponin and brain natriuretic peptide (BNP) may be elevated, as in many 
cases of heart failure.  Protein infiltration and deposition in the heart causes 
concentric wall thickening that may be mistaken for hypertrophy.  
Echocardiographic features common in cardiac amyloidosis include marked left 
ventricular (LV) wall thickening, thickened interatrial and interventricular septa, 
thickened valve leaflets, biatrial enlargement, and increased myocardial 
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echogenicity with a granular appearance (Figure 3)32.   Amyloid deposits in the 
heart contribute to stiffening and diastolic dysfunction, and eventually lead to 
diastolic heart failure, or heart failure with preserved ejection fraction (HFpEF). 
 
 
 
Figure 5. Echocardiographic features of cardiac amyloidosis. Echocardiograms 
compare a normal heart (left) with an amyloid-infiltrated heart (right).  Note the 
thickening of the walls and interventricular septum and the decreased size of the left 
ventricle. LV = Left Ventricle, RV = Right Ventricle, LA = Left Atrium, Ao = Aorta.  Figure 
reproduced from Quarta et al., 201227. 
 
 
VI. Diagnosis  
The diagnosis of AL amyloidosis is often delayed because the subtle 
presenting features can differ for each patient and typically resemble more 
common conditions.  Yet a timely diagnosis is important to halt the progression of 
the disease.  Certain clinical discoveries, though not highly specific to 
amyloidosis individually, may be indicative of it in combination.  Such features 
include nondiabetic nephrotic syndrome, enlarged cardiac mass in the absence 
of hypertension, increased cardiac biomarkers in the absence of primary heart 
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disease, unexplained purpura, or some of the clinical features described 
previously.  Once amyloidosis is recognized as a possible diagnosis, it must be 
confirmed by tissue biopsy, the precursor protein must be identified, and the 
extent of organ involvement should be determined.   
If AL-type amyloidosis is suspected, the patient must demonstrate a clonal 
plasma cell disorder.  Immunofixation electrophoresis of serum and urine and an 
Ig free light chain assay are required to show the presence of light chains31,33.  If 
amyloid deposits have already been found, these tests will indicate that the 
precursor protein responsible for the fibrils is AL.  Mass spectroscopy of amyloid 
deposits is also being explored as a means of reliable protein typing34. 
The diagnosis of amyloidosis must be confirmed histologically31.  Tissue 
stained with Congo red will exhibit apple-green birefringence under polarized 
light if amyloid fibrils are deposited there (Figure 6).  Sulfated Alcian blue stain is 
also used to demonstrate the presence of amyloid.  A biopsy of the suspected 
organ is the gold standard, but it can be risky and expensive.  Less invasive 
strategies exist to confirm the presence of amyloid deposits elsewhere in the 
body.  Although not as sensitive as a biopsy of the suspected organ, the 
aspiration of subcutaneous abdominal adipose tissue is highly specific and can 
offer over 80% sensitivity with proper Congo red staining and analysis35.  In 
combination with bone marrow biopsy, the sensitivity of the two tests together is 
even greater21.  Other possible sites of biopsy include the rectum and labial 
salivary glands36. 
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Figure 6. Cardiac tissue containing amyloid deposits displayed using various 
staining techniques.  This endomyocardial biopsy specimen shows evidence of 
amyloid deposits.  (A) Amyloid is apparent as pink extracellular deposits using a 
standard hematoxylin & eosin stain.  (B) Sulfated Alcian blue stain shows yellow 
myocytes surrounded by turquoise-green amyloid.  (C) Congo red stain using white light.  
(D) Congo red stain visualized under polarized light exhibits the classic apple-green 
birefringence of amyloid deposits.  Figure reproduced from Esplin & Gertz, 201337. 
 
 
VII. Evaluation and Prognostic Factors 
An evaluation of the extent of amyloidosis can be conducted for each of 
the various organ systems involved.  With any organ, biopsy evidence of amyloid 
deposit with clinical evidence of organ dysfunction is enough to consider that 
organ affected.  Biopsy evidence at an alternative site such as fat or rectum 
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along with certain clinical or laboratory criteria is also indicative of organ 
involvement, as catalogued in Table 3.  Examples include proteinuria 
demonstrating kidney involvement, hepatomegaly indicating liver involvement, 
and carpal tunnel syndrome indicating soft tissue or nerve involvement.  The 
extent of cardiac involvement should also be evaluated in particular due to its 
prognostic implications. 
Table 3. Indications of organ involvement in addition to biopsy of an alternative 
site31.  These criteria were developed at the 10th International Symposium on Amyloid 
and Amyloidosis. 
Organ Indicators 
Kidney • 24 hour urine protein > 0.5 g/day, predominantly albumin 
Heart • Echo: mean wall thickness > 12 mm with no other cardiac cause 
Liver • Total liver span > 15 cm in the absence of heart failure 
• Alkaline phosphatase > 1.5 times institutional upper limit of normal 
Peripheral 
Nerve 
• Sensory Loss 
• Symmetric lower extremity sensorimotor peripheral neuropathy 
Autonomic 
Nerve 
• Gastric-emptying disorder 
• Pseudo-obstruction 
• Voiding dysfunction 
GI Tract • Clinical symptoms with direct biopsy verification 
Lung • Clinical symptoms with direct biopsy verification 
• Interstitial radiographic pattern 
Soft Tissues • Macroglossia 
• Recurrent periorbital purpura 
• Carpal tunnel syndrome 
• Arthropathy 
• Myopathy 
• Claudication, presumed vascular amyloid 
• Skin 
 
The number of organs involved is indicative of a patient’s prognosis, but 
the single most relevant organ is the heart13,17.  Death was due to cardiac 
amyloidosis in 3 out of every 4 of patients who died at the Pavia Amyloid 
Center18.   An analysis of the outcomes of AL amyloidosis patients at the Mayo 
Clinic found that several factors, many of which are cardiac indicators, can 
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predict the likelihood of death within a year of diagnosis.  These included septal 
thickness, cardiac troponin T (cTnT), N-terminal pro-brain natriuretic peptide (NT-
proBNP), serum creatinine, serum uric acid, total bilirubin, alkaline phosphatase, 
bone marrow plasma cell percentage, and serum free light chains13.  Cardiac 
troponins are released as a result of cardiac muscle injury.  NT-proBNP is 
released from myocardial cells in response to wall stress and can indicate 
ventricular dysfunction.  The current staging system employed by the Mayo Clinic 
incorporates these two cardiac biomarkers with measurements of circulating free 
light chains in order to classify patients and attempt to predict their outcomes.  
Patients can be divided into Stages I-IV by assigning a score of 1 to each of the 
independent prognostic variables above the threshold values in Table 4 and 
adding the scores for each person38,39.   Given the significant impact of cardiac 
involvement on patient prognosis and the underlying cause of AL amyloidosis in 
the plasma cell’s production of light chains, it is understandable that markers of 
cardiac dysfunction and levels of free light chains are powerful indicators of 
patient outcome. 
Table 4. Prognostic indicators for patient staging39.  Values above the following 
thresholds are indications of poor patient prognosis. They can be measured in the 
laboratory using various blood tests. cTnT = cardiac Troponin T, NT-proBNP = N-
terminal pro-brain natriuretic peptide, and FLC-diff = free light chain difference (the 
difference between involved and uninvolved light chain). 
Variable Threshold value 
cTNT 0.025 ng/mL 
NT-proBNP 1,800 pg/mL 
FLC-diff 18 mg/dL 
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VIII. Treatment Options 
Treatment for AL amyloidosis is challenging because there is often a delay 
in diagnosis due to lack of suspicion, the patient is performing poorly at the time 
of diagnosis, and the treatment options themselves are limited.  Because heart 
failure is the common cause of death, treatment is directed toward improving 
cardiac function and eliminating the amyloid source.  However most standard 
heart failure therapies, such as angiotensin-converting enzyme (ACE) inhibitors, 
beta blockers, calcium channel blockers, and digoxin, have low efficacy and may 
even be associated with higher mortality rates5.  Since the cause of heart failure 
in cardiac amyloidosis is different from other types of heart failure, the targets for 
treatment are different as well. 
Ideally therapy for AL amyloidosis would be targeted toward stopping the 
production of light chain precursor proteins, preventing their misfolding and fibril 
formation, and promoting reabsorption of amyloid deposits, while also managing 
the symptoms of organ failure.  At present the clinically employed techniques are 
aimed at destroying the underlying plasma cell, thereby reducing the amounts of 
amyloidogenic light chains that are produced.  High-dose melphalan, an 
alkylating chemotherapy agent used to treat multiple myeloma, is often used in 
combination with other therapeutic agents such as prednisone and 
dexamethasone.  Melphalan and autologous peripheral blood stem cell 
transplantation can be used with carefully selected patients40.  Novel therapies 
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include the use of thalidomide, lenalidomide, pomalidomide, and 
bortezomib5,17,41.  Organ transplantation is controversial due to concerns about 
amyloid recurrence.  The choice of therapy depends on the number of organs 
involved, the status of the patient, and how well the side effects of therapy are 
tolerated.  Because patients are already very ill and the therapies they receive 
are toxic, there are serious risks of treatment-related mortality42.  The approach 
of using less harmful inhibitors and antibodies directed against serum 
amyloidogenic LC proteins or their tertiary structure may be the treatments of the 
future. 
 
IX. Objectives 
By learning more about how amyloidogenic light chains affect the heart, 
we will be able to develop therapeutic approaches that target this process.  In 
order to develop techniques that reduce the harmful effects of AL on the heart, 
we must first understand the mechanisms by which amyloidogenic light chains 
cause cardiac dysfunction.  It has been shown that AL can induce oxidative 
stress and cardiomyocyte contractile dysfunction25.  Studying cellular dysfunction 
and death may help us to determine the role of apoptosis and autophagy in 
cardiac dysfunction caused by AL.  If AL induces oxidative stress, and oxidative 
stress is capable of inducing autophagy, it is reasonable that autophagy might be 
involved in the cardiotoxicity of AL.  Since autophagy is not currently under 
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investigation, we sought to determine its role in amyloidosis.  Does AL induce 
autophagy?  If so, by what mechanism?   
It may be that autophagy is the heart’s attempt to maintain functionality 
while enduring the stresses induced by AL amyloidosis.  In many circumstances, 
autophagy constitutes a stress-adaptation pathway which promotes cell 
survival43.  Yet, paradoxically, it might contribute to nonapoptotic programmed 
cell death.  The focus of this research is to determine the role of autophagy in the 
pathogenesis of AL light chain-induced cardiac amyloidosis.
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MATERIALS & METHODS 
I. Chemicals and Reagents 
Sodium chloride (NaCl), potassium chloride (KCl), magnesium sulfate 
(MgSO4), potassium phosphate (KH2PO4), sodium bicarbonate (NaHCO3), 
calcium chloride (CaCl2), taurine, creatinine, L-carnitine, D-glucose, and Bovine 
Serum Albumin (BSA) were purchased from Sigma-Aldrich (St. Louis, MO).  The 
following buffers were purchased from BioRad: TG (25nM Tris and 192mM 
glycine), TGS (25mM Tris, 192mM glycine, and 0.1% sodium dodecyl sulfate), 
and PBS (10mM sodium phosphate, 150mM sodium choride).  The names, 
known functions, and sources of various MAPK inhibitors, chemicals, and light 
chain proteins used in this research are listed in Table 5. 
Table 5. Inhibitors, Chemicals, and Proteins. 
Name Known function Source 
UO126 Inhibitor of ERK1 and ERK244 Calbiochem® (San 
Diego, CA) 
SB203580 Inhibitor of p38-MAPK44 Calbiochem® (San 
Diego, CA) 
SP600125 Inhibitor of JNK44 Calbiochem® (San 
Diego, CA) 
Doxycycline hyclate Tetracycline antibiotic also shown to inhibit 
matrix metalloproteinases (MMPs), mitigate 
cardiac remodeling, and disrupt amyloid fibril 
formation 45,46  
Sigma-Aldrich  
(St. Louis, MO) 
Aldosterone Steroid hormone which acts in the kidney to 
cause water retention.  Also shown to increase 
cardiac remodeling, intracellular ROS, MMP 
activity, and phosphorylated (active) ERK1/247 
Sigma-Aldrich  
(St. Louis, MO) 
LC (non-
cardioyopathic) 
Component of immunoglobulins isolated from a 
human patient with no clinical evidence of 
cardiac amyloidosis 
Laboratory of Dr. 
Lawreen Connors 
(BUSM, Boston, MA) 
AL (cardiomyopathic) Amyloidogenic immunoglobulin light chains 
isolated from a human AL amyloidosis patient 
with cardiac involvement 
Laboratory of Dr. 
Lawreen Connors 
(BUSM, Boston, MA) 
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II. Isolation of Adult Rat Ventricular Myocytes (ARVM) 
 Adult rat ventricular myocytes (ARVM) were isolated as described 
previously by Essick et al.48.  The animals were treated according to the Guide 
for Care and Use of Laboratory Animals (Unites States National Institutes of 
Health).  The Institutional Animal Care and Use Committee at Boston University 
School of Medicine approved all study procedures related to handling of rats.  All 
efforts were made to minimize the number of animals used and their suffering. 
Healthy adult male Sprague-Dawley rats (approximately 200-220g) were 
obtained from Harlan Laboratories.  Rats were anaesthetized with 100mg/mL 
ketamine (Fort Dodge Animal Health, Fort Dodge, IA) and 20mg/mL xylazine 
(Lloyd Laboratories, Shenandoah, IA) at a ratio of 15:1 before the hearts were 
harvested and infused with K-H Buffer (118mM NaCl, 4.7mM KCl, 1.2mM 
MgSO4, 1.2mM KH2PO4, 25mM NaHCO3, and 12mM dextrose) until all blood 
was removed.  Hearts were then perfused for 20 minutes with Enzyme 1 
(65mg/mL collagenase and 40mg/mL hyaluronidase [Worthington Biochemical 
Corporation, Lakewood, NJ] in K-H Buffer).  The right ventricle was removed and 
the remaining tissues were digested in Enzyme 1 containing 0.018mg/mL trypsin, 
0.018mg/mL DNAse, and 1mM CaCl2 at 37°C for 30 minutes.  Tissues were 
filtered through 80-micron mesh gauze, washed with Wash Buffer (1:1 DMEM:K-
H Buffer) and concentrated through centrifugation at 500 rpm at 4°C for 3 
minutes.  DMEM is Dulbecco’s Modified Eagle Medium (Gibco®) containing 
100Units/mL penicillin and 100µg/mL streptomycin (PenStrep, Gibco ®).  The 
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cellular pellet was resuspended in Wash Buffer, run through DMEM containing 
64.5mg/mL BSA, and allowed to settle by gravitational force.  The resulting pellet 
was resuspended in DMEM. 
Cells were then plated non-confluently on laminin-coated (Gibco®, 
0.067mg/mL in DMEM) plastic culture dishes and incubated at 37°C for 1 hour.  
Prior to treatment, cells were maintained at 37°C for approximately 30 minutes in 
ACCT medium (DMEM containing, 2mg/mL BSA, 2mM L-carnitine, 5mM 
creatinine, and 5mM taurine). The cells were then subjected to various 
treatments as described in the following section. 
III. Treatment of Isolated ARVM 
Plated ARVM were subjected to various treatments for 24 hours, including 
a vehicle control without any treatment (Table 6).  Non-cardiomyopathic Light 
Chains (LC-noncmp) were used as a negative control because the human 
subjects from whom they were obtained showed no cardiac involvement.  
Aldosterone at a pathologically high concentration was used as a positive control 
because it has been shown to induce MAPK-dependent cardiac remodeling and 
an increased intracellular reactive oxygen species (ROS)47,49.  In some 
instances, the cells were treated with a specific MAPK inhibitor for 30 minutes 
prior to the addition of AL. 
After treatment, ARVM were placed on ice and rinsed twice with 
phosphate-buffered saline (PBS, 10mM sodium phosphate, 150 mM sodium 
chloride, Bio-Rad Laboratories).  ARVM were lysed using Cell Lysis Buffer (Cell 
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Signaling Technology, Danvers, MA), scraped from their plates, and centrifuged 
at 10,000 rpm for 12 minutes at 4°C to acquire cellular proteins in the 
supernatant.  The supernatant was collected and stored at -80°C.  Protein 
concentration was determined by Bradford Protein Assay (Bio-Rad Laboratories). 
 
Table 6. ARVM Treatment Conditions 
Condition Pretreatment 
(30 minutes) 
Treatment 
(24 hours) 
Control None None 
Negative Control None 20 mg/L LC-noncmp 
Positive Control None 1µM Aldosterone 
AL None 20 mg/L AL 
UO126 10 µM UO126 No additional treatment 
AL + UO126 10 µM UO126 20 mg/L AL 
SB203580 3 µM SB203580 No additional treatment 
AL + SB203580 3 µM SB203580 20 mg/L AL 
SP600125 2 µM SP600125 No additional treatment 
AL + SP600125 2 µM SP600125 20 mg/L AL 
Doxycycline (Dox) 50 µg/mL Dox No additional treatment 
AL + Doxycycline 50 µg/mL Dox 20 mg/L AL 
 
IV. Western Blotting 
 Cellular contents of autophagy-related proteins were analyzed with an 
immunoblotting assay.  Cellular lysate samples were subjected to SDS-PAGE 
(12% tris-glycine gels, Lonza, Rockland, ME) and transferred to 0.45µm pore 
Amersham Hybond™-P membranes (GE Healthcare, Little Chalfont, 
Buckinghamshire, UK).  Membranes were probed for autophagic proteins with 
the following polyclonal antibodies: anti-LC3 (1:3000) (Novus Biologicals, 
Littleton, CO) and anti-ATG4B (1:1000) (Cell Signaling Technology, Danvers, 
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MA).  Membranes were also probed for total and phosphorylated ERK using a 
polyclonal antibody against p44/42 MAPK (Total ERK1/2) (1:1000) and 
monoclonal antibody against Phospho-p44/42 MAPK (Phospho-ERK1/2) 
(1:1000) (Cell Signaling Technology, Danvers, MA), respectively.  A monoclonal 
antibody against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
used as a loading control (Abcam, Cambridge, MA).  Membranes were then 
probed with either goat anti-rabbit or goat anti-mouse horseradish peroxidase 
conjugated secondary antibodies (1:5000) (Santa Cruz Biotechnology, Santa 
Cruz, CA).  Blots were detected with Amersham ECL™ Western Blotting 
Detection Reagents (GE Healthcare, Little Chalfont, Buckinghamshire, UK).  
Chemiluminescence was quantified by densitometry using ImageJ measuring 
software (National Institutes of Health).  Protein expression was normalized for 
equal protein loading, and data is expressed in arbitrary units relative to GAPDH 
control.
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RESULTS 
I. AL Does Not Induce Autophagy via ERK1/2 
In order to test the hypothesis that AL activates autophagy by mediating 
the ERK1/2 pathway, we treated ARVM with human LC from a patient with AL 
amyloidosis with cardiac involvement (AL), light chains isolated from a patient 
without clinical evidence of cardiomyopathy (LC-noncmp), or vehicle control 
(Control) in the presence or absence of UO126, a selective ERK1/2 inhibitor.  We 
then examined the protein expression of LC3II by immunoblotting (Figure 7).  
LC3II is formed from the conjugation of LC3I with phosphatidylethanolamine in 
order to associate with the autophagosome membrane, a step in the process of 
autophagy28,50,51.  LC3II is used as a measure of autophagosome formation and 
therefore autophagy. 
 AL did not induce autophagy, and the inhibition of ERK1/2 by UO126 did 
not have any notable effect.  LC3II levels induced by AL, UO126, and AL+UO126 
did not significantly differ from the vehicle control.  However, LC3II levels were 
significantly higher in cardiomyocytes exposed to LC-noncmp than AL (p<0.05).  
These data suggest that AL does not induce autophagy through the ERK1/2 
pathway. 
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Figure 7. AL does not induce autophagy through ERK1/2. Adult rat ventricular 
cardiomyocytes were exposed to vehicle (Control), 20mg/L human non-cardiomyopathic 
light chains (LC-noncmp), 1µM Aldosterone, and 20mg/L human AL in the presence and 
absence of pretreatment with 10µM UO126, a selective ERK1/2 inhibitor.  The resulting 
levels of LC3II in cell lysates were analyzed by Western blotting.   (A) Bar graph 
summarizes the data from five independent experiments (n=5).  LC3II levels are 
expressed in arbitrary units relative to the loading control GAPDH.  LC3II levels in AL, 
UO126, and AL+UO126 conditions did not significantly differ.  LC3II levels in AL were 
not different from control levels, but significantly different from LC-noncmp LC3II levels 
(p<0.05). (B) Representative Western blot.  
LC3I 
LC3II 
 
GAPDH 
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We continued to explore the potential of AL to activate the ERK1/2 
pathway by comparing phosphorylated (active) ERK (p-ERK) to total ERK (ERK) 
under various experimental conditions.  ARVM were treated with vehicle control, 
aldosterone, LC-noncmp, and AL in the presence or absence of pretreatment 
with the matrix metalloproteinase (MMP) inhibitor doxycycline, which has also 
been shown to decrease amyloid fibril formation and levels of p-ERK in murine 
models45,52.  Both p-ERK and total ERK expression were determined in the 
ARVM cellular lysates. 
As before, p-ERK/ERK ratios in ARVM treated with AL, doxycycline, and 
AL+doxycycline did not differ from the average control ratio.  Unfortunately, the 
aldosterone positive control levels were quite variable and the average level was 
also not significantly different from controls.  Several individual experiments were 
excluded in which the positive aldosterone control levels of pERK/ERK were not 
elevated above vehicle control levels.  This may be attributed to the use of a 
lower 50nM dose of aldosterone instead of the pathologically high 1µM dose in 
these experiments.  However a 50nM dose of aldosterone has been previously 
shown to induce ERK phosphorylation in ARVM47.  These data suggest that AL 
did not induce ERK expression, but further study is suggested using high-dose 
aldosterone as a positive control. 
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Figure 8.  AL does not promote the phosphorylation of ERK. Adult rat ventricular 
cardiomyocytes were exposed to vehicle (Control), 20mg/L human non-cardiomyopathic 
light chains (LC-noncmp), 50nM aldosterone, and 20mg/L human AL in the presence 
and absence of pretreatment with doxycycline.  The resulting levels of phosphorylated 
ERK (p-ERK) and total ERK (ERK) in cell lysates were analyzed by Western blotting.   
(A) Bar graph summarizes the data from three independent experiments (n=3).  Ratios 
of p-ERK/ERK were normalized to the loading control GAPDH and expressed in arbitrary 
units. (B) Representative Western blot.  
A 
B p-ERK 
ERK 
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II. AL Does Not Induce Autophagy via p38 
AL has been shown to induce cardiomyocyte apoptosis through the 
activation of p38α MAPK25.  The p38 pathway has also been implicated in the 
induction and suppression of autophagy28,53.  We therefore examined whether AL 
promotes autophagy through p38 MAPK.  ARVM were treated with vehicle 
control, aldosterone, LC-noncmp, and AL in the presence or absence of 
pretreatment with SB203580, a selective p38 inhibitor.  We then employed 
Western blotting to examine the production of LC3II as a measure of autophagy 
(Figure 9). 
We observed that LC3II levels in cells treated with LC-noncmp and 
aldosterone were slightly elevated, but AL-treated cells remained near control 
levels.  The introduction of SB203580 did not mediate the effects of AL on LC3II 
protein production, but this is not unexpected given that the AL effects were 
minimal.  Statistical analysis of these data from four independent experiments 
revealed that LC3II protein levels in experimental conditions did not significantly 
differ from vehicle control levels (p>0.5). 
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Figure 9.  AL does not induce autophagy through p38 MAPK. Adult rat ventricular 
cardiomyocytes were exposed to vehicle (Control), 20mg/L human non-cardiomyopathic 
light chains (LC-noncmp), 1µM aldosterone, and 20mg/L human AL in the presence and 
absence of pretreatment with 3µM SB203580, a selective p38 MAPK inhibitor.  The 
resulting levels of LC3II in cell lysates were analyzed by Western blotting.  (A) Bar graph 
summarizes the data from four independent experiments (n=4).  LC3II levels are 
expressed in arbitrary units relative to the loading control GAPDH.  LC3II levels in AL, 
SB203580, and AL+SB203580 conditions did not significantly differ from control levels 
(p>0.5). (B) Representative Western blot. 	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III. AL Does Not Induce Autophagy via JNK 
  Since stress-, starvation-, and ROS-induced autophagy has been shown 
to occur through activation of JNK pathways, we next tested the hypothesis that 
AL promotes autophagy through JNK28,53,54.  ARVM were treated with vehicle 
control, aldosterone, LC-noncmp, and AL in the presence or absence of 
pretreatment with SP600125, a selective JNK inhibitor.  Western blotting was 
used to examine the amount of LC3II in ARVM cell lysates as a measure of 
autophagy (Figure 10).  As previously observed, the levels of LC3II in ARVM 
treated with AL did not vary from control levels.  LC3II levels in AL, SP600125, 
and AL+SP600125 treatment conditions were not significantly different from 
control LC3II levels or from one another.  However the addition of SP600125 
appeared to cause a slight increase in autophagy. 
After conducting our examination of LC3II, we were able to probe the 
same membranes for ATG4B (Figure 11).  ATG4B is a cysteine protease 
necessary for the generation and regulation of autophagosome membranes and 
is therefore another indicator of autophagy55.  Both the aldosterone positive 
control and LC-noncmp treatment conditions revealed significantly elevated 
levels of ATG4B (p<0.05).  However, as with LC3II, the ATG4B levels in AL, 
SP600125, and AL+SP600125 treatment conditions were not significantly 
different from control LC3II levels or from each other.  The addition of SP600125 
appeared to prompt a slight increase in autophagy. 
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Figure 10. AL does not induce autophagy through JNK: LC3II results. ARVM were 
exposed to vehicle (Control), 20mg/L human non-cardiomyopathic light chains (LC-
noncmp), 1µM Aldosterone, and 20mg/L human AL in the presence and absence of 
pretreatment with 2µM SP600125, a selective JNK inhibitor.  The resulting levels of 
LC3II in cell lysates were analyzed by Western blotting.   (A) Bar graph summarizes data 
from four independent experiments (n=4).  LC3II levels were normalized to the loading 
control GAPDH and expressed in arbitrary units.  LC3II levels in AL, SP600125, and 
AL+SP600125 conditions did not significantly differ from control levels (p>0.1).  (B) 
Representative Western blot. 
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Figure 11. AL does not induce autophagy through JNK: ATG4B results. ARVM 
were exposed to vehicle (Control), 20mg/L human non-cardiomyopathic light chains (LC-
noncmp), 1µM aldosterone, and 20mg/L human AL in the presence and absence of 
pretreatment with 2µM SP600125, a selective JNK inhibitor.  The resulting levels of 
LC3II in cell lysates were analyzed by Western blotting.   (A) Bar graph summarizes data 
from four independent experiments (n=4).  ATG4B levels are expressed in arbitrary units 
relative to the loading control GAPDH.  Both aldosterone and LC-noncmp significantly 
increase ATG4B protein expression (p<0.05), but similar to LC3II, the AL, SP600125, 
and AL+SP600125 conditions did not significantly differ from control levels of ATG4B. 
(p>0.1). (B) Representative Western blot. 
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DISCUSSION 
I. Function of Cardiac Autophagy 
The functional role of autophagy remains uncertain (Figure 12).  Basal 
physiological levels of autophagy are responsible for degrading aged or 
damaged portions of the cell like proteins and organelles.  It is a primitive and 
important mechanism in maintaining cellular homeostasis and adapting to 
situations such as nutrient depletion by degrading, remodeling, and recycling 
existing cellular components.  This feature is useful for cells adapting to changes 
in metabolic supply and temporary external stresses.  Autophagy is critical for 
murine embryonic development and is an important means of supplying nutrients 
to the newborn after the abrupt interruption of the placental nutrient supply56–58. 
  
 
Figure 12. Autophagy: Good or Bad? Autophagy has various physiological roles, 
including cellular housekeeping and defense against metabolic deficiency.  Under 
normal circumstances, autophagy constitutes a mechanism of turning over proteins and 
organelles, adapting to stress, and promoting cell survival.  Paradoxically, it can also 
constitute a form of non-apoptotic cell death.  The effects of autophagy vary depending 
on the tissue in which it occurs and the type and duration of stimulus59.  Its possible role 
in both the prevention and causation of various diseases is currently a focus of research. 
Figure adapted from Levine and Kroemer, 200843. 
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Deficiency of basal autophagy has been implicated in heart disease60,59,61.  
For example, the cardiac-specific loss of autophagy in a murine model has been 
shown to induce cardiomyopathy62.  In an in vitro study mimicking myocardial 
infarction, the suppression of autophagy enhanced cardiac death63.  This 
suggested that ischemia-induced autophagy can be protective.  In diabetic mice, 
enhanced autophagy was associated with an improvement of cardiac function64.  
In human patients with Danon disease, a lysosomal membrane protein called 
LAMP2 is mutated and blocks the fusion of autophagosomes with 
lysosomes60,65,66.  This leads to the accumulation of aged proteins and 
autophagosomes filled with undigested cellular materials, and it manifests as 
cardiomyopathy, heart failure, and mental retardation.  Murine models lacking 
LAMP2 exhibit cardiac hypertrophy and decreased contractile function67.  These 
results indicate the importance of constitutive autophagy in cellular homeostasis 
under basal conditions, and show that it can be beneficial in some disease 
states. 
On the other hand, excessive activation of autophagy may be maladaptive 
and can lead to non-apoptotic cell death.  Autophagy has been implicated in the 
progression of hypertrophic remodeling60.  For example, Zhu et al. found that 
autophagy was activated at various stages of heart failure induced by 
hypertension, and that partial suppression of autophagic activity in severe heart 
failure attenuated pathological remodeling68.  Wang et al. postulate that 
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autophagy activated during ventricular hypertrophy serves to maintain cellular 
homeostasis, and excessive autophagy eliminates essential cellular components 
and provokes cell death, thereby contributing to hypertension-related heart 
disease (Figure 13).  In the case of ischemia/reperfusion injury, it has been 
shown that autophagy might not always be cytoprotective.  Some researchers 
postulate that reperfusion is followed by a maladaptive “second wave” of 
autophagic activity60,59,63.  This suggests that autophagy may be protective during 
ischemia but detrimental during reperfusion.  Thus cardiomyocyte autophagy and 
its effects may vary in response to different stimuli and conditions.  Its functional 
role in various diseases continues to be explored. 
 
Figure 13. The role of autophagy in hypertensive heart disease. Wang et al. 
postulate that constitutive levels of autophagy are necessary for cell survival and that the 
inactivation of autophagy is maladaptive (Atg5-/-), especially in the case of post-mitotic 
cells that must survive for long periods of time without replication.  Less drastic 
increases (Beclin1Tg, Transgenic) or decreases (Beclin1+/-) in autophagic activity 
relative to wild type (WT) have fewer physiological effects.  In the case of hypertension-
related heart disease, autophagy is activated in response to a growth stimulus such as 
increased hemodynamic stress.  Autophagic activity can be maladaptive in the case of 
severe, prolonged stress. Figure reproduced from Wang et al., 201060. 
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II. AL Does Not Induce Autophagy 	  
Cardiomyocyte autophagy has been shown to be both beneficial and 
deleterious, depending upon the type, extent, and duration of cellular stress.  Our 
data suggest that the stress caused to cardiomyocytes by 24 hours of AL 
exposure does not induce autophagy through ERK, p38, or JNK MAPK 
pathways.  If this were the case, we would have expected to see increased LC3II 
or ATG4B levels in AL-treated cardiomyocytes and that pretreatment with a 
MAPK inhibitor would attenuate those elevated autophagy measures.  Instead, 
average autophagic protein levels in AL-treated cardiomyocytes did not differ 
from controls in any of our experiments.  This suggests that not only does AL fail 
to induce autophagy through MAPK signaling pathways, but AL may not induce 
autophagy in the heart at all.  This conclusion contradicts previous unpublished 
work from our laboratory, which suggested that AL increases protein expression 
of ATG4B and LC3II. 
When considering why AL did not induce autophagy, one could postulate 
that 24 hours of exposure to AL-LC was not sufficient time to prompt autophagy 
in cardiomyocytes.  However our previous explorations of LC3II, ATG4B, and 
matrix metalloproteinase activity found that 24 hours was ample time to cause 
changes in cellular function.  Shi et al. also found 24 hours to be sufficient to 
induce contractile dysfunction and apoptosis in their exploration of the p38α 
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MAPK pathway25.  We therefore conclude that if AL were to induce autophagy, it 
should do so in 24 hours time. 
One surprisingly consistent trend was that noncardiomyopathic LC 
induced autophagy to a greater extent than AL.  This is especially notable in the 
significantly different LC3II measurements in Figure 7.  Given that the LC-
noncmp proteins were obtained from a patient without clinically evident cardiac 
involvement, it is possible that the light chains induce an autophagic process that 
is actually beneficial to the heart.  By failing to promote this advantageous 
mechanism, AL patients experience more perceptible cardiac dysfunction. 
Another interesting trend was shown by the effect of JNK inhibition on 
autophagy measurements (Figures 10 and 11).  With the addition of JNK inhibitor 
SP600125, levels of autophagic proteins LC3II and ATG4B increased.  This 
could imply a role of the JNK pathway in the prevention of autophagy, in contrast 
to literature reports suggesting it participates in the activation of autophagic 
mechanisms53,61.  Further study is necessary to confirm such a hypothesis. 
 
III. Limitations of the Study 
It is difficult to draw conclusions from such a small study.  In order to 
address the issue of statistical significance, we would need to augment the 
power of our studies.  This can be done by simply increasing sample sizes and 
thereby decreasing the ability of variance to affect our results. 
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It is also important to remember that this study was conducted using 
human proteins in rat cardiomyocytes.  Because the same protein was used in 
every ARVM treatment, the rat cardiomyocytes should have behaved similarly to 
each other.  However this does not guarantee that they behaved in the same way 
as human cardiomyocytes would.  While mammalian models are very similar to 
humans, the specific biochemical pathways may vary and the addition of a 
foreign protein may cause subtly different reactions to occur. However others 
have used the same human protein with exposure to rat cardiomyocytes23,24. 
Another limitation is that the AL proteins were all obtained from one 
patient, as were the LC proteins.  Clinically AL amyloidosis can present itself in a 
wide variety of tissues and to varying extents.  The exact AL protein sequence 
can even differ from person to person, lending further variability to the disease 
presentation and its effects.  Our findings would therefore be strengthened by the 
inclusion of light chains from multiple patient sources.  This would eliminate the 
possibility of our results being an isolated phenomenon reflective of only one 
person. 
In vitro findings do not necessarily reflect in vivo results, which is why our 
focus was on mechanisms in specific biochemical pathways.  Conducting 
research in vivo and analyzing phenotypic results would be an excellent 
complement to this study.  Unfortunately, no mammalian models exist for cardiac 
amyloidosis.  Ward et al. were able to develop transgenic mice that expressed 
AL light chains through a cytomegalovirus promoter and subsequently developed 
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amyloid deposits, but no cardiac phenotype was observed45.  AL can be injected 
or infused through an osmotic pump, but amounts of human-derived AL protein 
are limited.  Currently zebrafish with AL injected at the embryonic stage are being 
developed as a model for AL cardiac amyloidosis, and may provide a future in 
vivo model69. 
 
IV. Future Directions 
Continuing to explore the underlying mechanisms of how amyloidogenic 
light chains cause cardiac dysfunction remains a promising avenue toward 
developing therapeutic interventions that reduce the harmful effects of AL light 
chains on the heart.  While further exploration is necessary to confirm our 
findings, the preliminary data suggests that the role of autophagy in the 
pathogenesis of AL amyloidosis is limited.  Its beneficence or harmfulness also 
remains incompletely characterized.  Although the mystery of cardiac autophagy 
persists, it may be prudent to further investigate the means by which AL induces 
oxidative stress and apoptosis, since their involvement in amyloidogenic cardiac 
dysfunction has already been shown. 
In order to address the functional role of cardiac autophagy in amyloidosis, 
we could study the effects of LC and AL proteins in autophagy-deficient mice.  
After utilizing siRNA to inhibit the expression of autophagy-related proteins such 
as LC3II and ATG4B, we could observe the phenotypic effects of LC and AL 
treatments.  This can be accomplished through measurements of cardiac 
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markers such BNP and troponin.  We could also study the effect on cardiac 
remodeling by measuring MMPs.  By introducing AL in an instance where 
autophagy has been eliminated, we will be able to determine whether 
autophagy’s effects in amyloidosis are beneficial or not.  If the role of autophagy 
in AL amyloidosis is minimal as our current data suggests, then the phenotype of 
autophagy-knockout mice should be comparable to normal mice after exposure 
to AL. 
 
V. Conclusion 
AL amyloidosis is caused by the plasma cell production of light chains that 
are misfolded and aggregated.  They disrupt normal organ function by depositing 
themselves in tissues.  Amyloidogenic light chain deposition is especially 
damaging to the heart.  Free light chains have also shown to be toxic, leading to 
cardiomyocyte contractile dysfunction and apoptosis through p38α MAPK.  This 
study found that AL light chains did not contribute to autophagy through ERK1/2, 
p38, or JNK MAPK pathways. Further studies are required to understand the 
causes of cardiac dysfunction due to light chains.  Elucidating the underlying 
mechanisms of light chain toxicity and aggregation could contribute to the 
development of diagnostic, prognostic, and treatment strategies for AL 
amyloidosis patients.
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SKILLS 
 
 
 
 
 
 
 
 
• Proficient in Meditech Electronic Medical Record system, Beckman-Coulter LH 780 
& 750 Hematology Analyzers with Slide Maker and Stainer, Ortho Clinical 
Diagnostics Vitros F5.1 & 350 Chemistry Analyzers, Abbot Architect i1000 and 
Axsym Analyzers, Iris Diagnostics iQ200 Urine Analyzer 
• Experienced with Microsoft Office (Word, Excel, PowerPoint), ChemDraw, UCSF 
Chimera, Kaleidagraph  
• Familiar with basic chemistry and molecular biology laboratory procedures and 
analysis techniques, including gel electrophoresis, Western blotting, PCR, 
expression cloning, light microscopy, UV-Vis spectroscopy, column 
chromatography, thin layer chromatography, densitometry, NMR, and GCMS 
• Excellent fundamental laboratory and notebook-keeping practices, organizational 
and data entry skills 
• Outstanding filing, organizational, and data entry skills 
 
